Minerva Neurosciences (NERV) Current Deferred Revenue (2014 - 2016)

Minerva Neurosciences (NERV) posted Current Deferred Revenue of $3.5 million for Q3 2016, up 42801.4% on a QoQ basis from $8237.0 in Q1 2015.

Minerva Neurosciences (NERV) Current Deferred Revenue (2014 - 2016) Analysis & Trends

Minerva Neurosciences' Current Deferred Revenue history runs 3 years deep, the most recent figure standing at $3.5 million for Q3 2016.

Quarterly Current Deferred Revenue changed N/A year-over-year to $3.5 million in Q3 2016, while the trailing twelve-month figure through Sep 2016 was $3.5 million (changed N/A YoY) and the FY2014 annual result came in at $7226.0, changed N/A from the prior year.
Current Deferred Revenue was $3.5 million for Q3 2016 at Minerva Neurosciences, up from $8237.0 in the prior quarter.
Across five years, Current Deferred Revenue topped out at $3.5 million in Q3 2016 and bottomed at $7226.0 in Q4 2014.
A 3-year average of $1.2 million and a median of $8237.0 in 2015 frame the typical range for Current Deferred Revenue.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Minerva Neurosciences	195.10 Mn	195.10 Mn	-

Download Data